Evrys Bio: Funding, Investors & Team (Sep 2026)
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.
Evrys Bio has raised $34.3M across 1 funding round on record, the most recent a Grant of $34.3M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Evrys Bio Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Evrys Bio Funding Rounds
Evrys Bio Founders and Leadership Team
No contact details are on record for this team yet.
Evrys Bio Funding Compared to Other Biotechnology Startups
Evrys Bio's latest round of $34.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evrys Bio in Biotechnology and Doylestown
Companies Similar to Evrys Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Evrys Bio Funding FAQs
What does Evrys Bio do?
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.
How much funding has Evrys Bio raised?
Evrys Bio has raised $34.3M across 1 round on record. The most recent is a Grant of $34.3M announced in Jul 2021.
When did Evrys Bio last raise funding?
Evrys Bio's most recent funding round on record is a Grant of $34.3M, announced in Jul 2021.
Who is the CEO of Evrys Bio?
Lillian Chiang is listed as CEO at Evrys Bio.
Where is Evrys Bio headquartered?
Evrys Bio is based in Doylestown, Pennsylvania, United States.
How many employees does Evrys Bio have?
Evrys Bio is in the 11-50 employee band.
How does Evrys Bio's funding compare to other Biotechnology startups?
Evrys Bio's latest round of $34.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Evrys Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evrys Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.